Evidence map›Paper›PMID 38831230›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study.

Amanda Landers, Helen Brown, Juhaina Al Ruheili, Kylie Russell, Clare McKenzie, Meera R Agar, Vanessa M Yenson, Kate Clarke, John Windsor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amanda LandersDepartment of Medicine, University of Otago, 2 Riccarton Ave, Christchurch Central, Christchurch, 8011, New Zealand. amanda.landers@otago.ac.nz.ORCID https://orcid.org/0000-0002-7385-3739
Helen BrownNurse Maude Hospice Palliative Care Service, Nurse Maude Association, Christchurch, New Zealand.
Juhaina Al RuheiliTe Whatu Ora, Wellington, New Zealand.
Kylie RussellNutrition and Dietetics, Te Whatu Ora Te Toka Tumai, Auckland, New Zealand.
Clare McKenzieNurse Maude Hospice Palliative Care Service, Nurse Maude Association, Christchurch, New Zealand.
Meera R AgarIMPACCT Centre, Faculty of Health, University of Technology Sydney, Sydney, Australia.
Vanessa M YensonIMPACCT Centre, Faculty of Health, University of Technology Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0002-7112-0785
Kate ClarkeTe Whatu Ora, Wellington, New Zealand.
John WindsorSurgical and Translational Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Funding

Canterbury Medical Research Foundation GIA 2021-03Health Research Council of New Zealand 21/906
6 · The paper itself

Abstract

purposeThis study investigated pancreatic enzyme replacement therapy (PERT) use in people diagnosed with pancreatic cancer in New Zealand (NZ) and Australia (AU).

methodsA cross-sectional survey study was conducted using a mixed-media campaign to recruit people with pancreatic cancer and collect information about current PERT use. The questionnaire gathered data on participant demographics, awareness of PERT, prescribing practices and efficacy of enzyme replacement.

resultsOver 300 people with pancreatic cancer were recruited, 135 from New Zealand and 199 from Australia. Every region, state and territory was represented except for the West Coast (NZ) and the Northern Territory (AU), the lowest populated areas in both countries. In New Zealand, 60% of participants had heard about PERT, compared to 69.3% in Australia. Dosing regimens were inconsistent in both countries, with 18% and 27% of participants being prescribed PERT considered best practice in New Zealand and Australia, respectively. Before PERT commencement, 70% of participants experienced symptoms of malabsorption, with all symptoms improving after therapy was established. The majority of participants were compliant with their medication.

conclusionPERT use in pancreatic cancer in New Zealand and Australia was highly variable and not compliant with international guidelines in which PERT is recommended as standard therapy. Enzyme replacement is effective for improving the symptoms of malabsorption in patients with pancreatic cancer. Clinician education may be needed to help improve the use of PERT in people with pancreatic cancer.

Indexed as

Enzyme Replacement TherapyPancreatic NeoplasmsAdultAgedAged, 80 and overAustraliaCross-Sectional StudiesFemaleHumansMaleMiddle AgedNew ZealandSurveys and QuestionnairesEnzyme replacement therapyPancreatic cancerPancreatic exocrine insufficiencySymptom management

Identifiers

PMID38831230
PMCPMC11147847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.